buoyantintelligence
  • 01Overview
  • 02Portfolio
  • 03Company Atlas
    • Buoyant book
    • All listed companies
  • 04Screener & valuation
  • 05House view
  • 06Markets
  • 07India top-down
  • 08Investors
  • 09Library & data
Release
August 2026 · rev 1
Opportunities PMS · Published
As at 31 Aug 2026 · IST₹ · ₹ cr · BSE 500 TRI
Present
Internal working platform. Published figures are extracted from the August 2026 source package and reviewed; reference prices and fundamentals are unlicensed working data, not for redistribution. Past performance is not indicative of future returns.
All listed companies/Strides Pharma Science Limited
03 /Listed universe · Healthcare · Pharmaceuticals

Strides Pharma Science Limited.

Value itCompareScreener.in ↗Tijori ↗NSE ↗BSE ↗
Snapshot

Healthcare · Pharmaceuticals

Strides Pharma Science Limited, a pharmaceutical company, engages in the development, manufacturing, and marketing of pharmaceutical products in North America, Australia, Africa, Europe, India, the rest of Asia, and internationally. The company offers generic finished dosage formulations in a range of dosages, such as tablets, hard capsules, sachets, liquids, nasal sprays, topical formulations, and controlled substances; and therapeutic products, including antivirals, antibiotics, NSAIDs, and allergy treatment. It also provides branded generics, prescription medicines, and over-the-counter products for infectious diseases, pain management, cardiology, and wellness; and prescription generics for anti-infectives, CNS, cardiovascular, gastroenterology, pain management, and specialty products. The company was formerly known as Strides Shasun Limited and changed its name to Strides Pharma Science Limited in July 2018. Strides Pharma Science Limited was incorporated in 1990 and is headquartered in Bengaluru, India.

Market cap
₹11,204 cr
P/E (TTM)
18.5
P/B (latest)
3.6
ROE (TTM)
17.9%
ROCE (TTM)
23.3%
Sales CAGR 3y
9.6%
PAT CAGR 3y
0%
Debt / equity
0.54x
Promoter
27.9%
Dividend yield
0.41%
Size
Micro
Codes
STAR · 532531
Price

₹1,151.4 · 28 Sept 2026

1M
+12.9%
3M
+6.4%
6M
+22.5%
YTD
+26.3%
1Y
+45.3%
3Y
+135.9%
5Y
—
vs 52w high
−6.8%

52-week ₹793.55 – ₹1,235.1 · ADTV ₹39.0 cr · price-only.

Trend

Sales and net profit by fiscal year, ₹ crore

Not in the Buoyant book: no house thesis or target is carried. Exchange masters, Tijori and the reference price feed as stated on each tab. All listed companies · NSE EQ